ASH 2019 | iFCG proves promising for IGHV-mutated CLL
Nitin Jain
• 7 Dec 2019
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results from the ongoing phase II trial (NCT02629809) of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) that have a mutated IGHV status but the absence of del(17p)/mutated TP53. The iFCG regimen with only three cycles of chemotherapy proved to be an effective time-limited regimen. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
